Christopher Ramsden, M.D., Ph.D.

Investigator

Lipid Peroxidation Unit

NIA

251 Bayview Boulevard
Suite 100
Baltimore, MD 21224

410-558-8369

chris_ramsden@nih.gov

Research Topics

The objectives of the Lipid Peroxidation Unit are: (1) to delineate the roles of lipid peroxidation and lipid-related degeneration in age-related diseases, with an emphasis on chronic pain and neurodegenerative diseases, and (2) to translate these discoveries into targeted, safe and effective diet and drug-based treatments. The Unit applies an interdisciplinary, translational approach—comprising randomized controlled trials, postmortem studies, missing data recovery, synthetic and analytical chemistry, immunohistochemistry (IHC) and multiplex-IHC, and cellular models—to achieve these objectives.

Biography

Dr. Ramsden is a Clinical Investigator in the Intramural Program of the NIH and CAPT in the Commissioned Corps of the U.S. Public Health Service. After completing a medical internship and then residency training in Physical Medicine & Rehabilitation at the Rehabilitation Institute of Chicago, he was a clinical research fellow at UNC-Chapel Hill before joining the Intramural Program of the NIAAA in 2009. In 2016, he was appointed to a Clinical Tenure-Track position as the Head of the Lipid Peroxidation Unit, within the Laboratory of Clinical Investigation in the NIA in Baltimore, MD, with a joint Tenure-Track appointment in the Intramural Program of NIAAA in Bethesda, MD. Dr. Ramsden leads an interdisciplinary, translational research program investigating the roles of lipid mediators and lipid-related mechanisms underlying the pathogenesis of chronic pain and Alzheimer’s disease.

Selected Publications

  1. Ramsden CE, Keyes GS, Calzada E, Horowitz MS, Zamora D, Jahanipour J, Sedlock A, Indig FE, Moaddel R, Kapogiannis D, Maric D. Lipid Peroxidation Induced ApoE Receptor-Ligand Disruption as a Unifying Hypothesis Underlying Sporadic Alzheimer's Disease in Humans. J Alzheimers Dis. 2022.

  2. Ramsden CE, Zamora D, Faurot KR, MacIntosh B, Horowitz M, Keyes GS, Yuan ZX, Miller V, Lynch C, Honvoh G, Park J, Levy R, Domenichiello AF, Johnston A, Majchrzak-Hong S, Hibbeln JR, Barrow DA, Loewke J, Davis JM, Mannes A, Palsson OS, Suchindran CM, Gaylord SA, Mann JD. Dietary alteration of n-3 and n-6 fatty acids for headache reduction in adults with migraine: randomized controlled trial. BMJ. 2021;374:n1448.

  3. Ramsden CE, Faurot KR, Zamora D, Suchindran CM, MacIntosh BA, Gaylord S, Ringel A, Hibbeln JR, Feldstein AE, Mori TA, Barden A, Lynch C, Coble R, Mas E, Palsson O, Barrow DA, Mann DJ. Targeted alteration of dietary n-3 and n-6 fatty acids for the treatment of chronic headaches: a randomized trial. Pain. 2013;154(11):2441-2451.

  4. Ramsden CE, Zamora D, Majchrzak-Hong S, Faurot KR, Broste SK, Frantz RP, Davis JM, Ringel A, Suchindran CM, Hibbeln JR. Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73). BMJ. 2016;353:i1246.

  5. Ramsden CE, Zamora D, Leelarthaepin B, Majchrzak-Hong SF, Faurot KR, Suchindran CM, Ringel A, Davis JM, Hibbeln JR. Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. BMJ. 2013;346:e8707.


This page was last updated on June 7th, 2022